Table 3.
LncRNAs Involved in Endocrine Therapy Resistance of Breast Cancer
| Drug | lncRNA | Dysregulation | Effect on Drug Resistance | Target/Pathway/Mechanisms | Refs |
|---|---|---|---|---|---|
| Tamoxifen | CYTOR | ↑ | Promoting | miR-125a-5p/SRF/MAPK | [81] |
| LOL | ↑ | Promoting | let-7 family | [82] | |
| DSCAM-AS1 | ↑ | Promoting | miR-137/ESP8, GREB1 | [83,84] | |
| TMPO-AS1 | ↑ | Promoting | estrogen signaling | [85] | |
| ROR | ↑ | Promoting | miR-205/ZEB1/ZEB2, MAPK/ERK/DUSP7, autophagy | [86–88] | |
| CCAT2 | ↑ | Promoting | apoptosis | [89] | |
| BCAR4 | ↑ | Promoting | ERBB2/ERBB3 | [90] | |
| ADAMTS9-AS2 | ↑ | Promoting | miR-130a-5p/PTEN | [91] | |
| Linc00894-002 | ↑ | Reversing | miR-200a-3p/miR-200b-3p/TGF-β2/ZEB1 | [92] | |
| AIs | / | / | / | / | / |
Notes: “↑” represents upregulation; “↓” represents downregulation; “/” represents not mentioned.